Danaher to buy Cepheid for about $4 billion, including debt

(Reuters) – Danaher Corp said on Tuesday it would buy molecular diagnostics company Cepheid in a deal valued at $4 billion, including debt, to strengthen its diagnostics unit.

(Reuters) – Danaher Corp said on Tuesday it would buy molecular diagnostics company Cepheid in a deal valued at $4 billion, including debt, to strengthen its diagnostics unit.
Original Article

more recommended stories